Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement

This publication has 12 references indexed in Scilit:

• Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
  Blood Advances, 2020
• Multiple myeloma with central nervous system relapse
  Haematologica, 2020
• Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
  New England Journal of Medicine, 2019
• Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
  Blood, 2018
• Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
  Clinical Cancer Research, 2018
• Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice
  American Journal of Hematology, 2016
• Pomalidomide
  Blood, 2013
• Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
  PLOS ONE, 2013
• Effective treatment of pomalidomide in central nervous system myelomatosis
  Leukemia & Lymphoma, 2012
• Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
  Cancer, 2011